Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial

Yan Jiang1,*
Zhen-Lin Zhang2,*
Zhong-Lan Zhang3
Han-Min Zhu4
Yi-Yong Wu3
Qun Cheng3
Feng-Li Wu3
Xiao-Ping Xing1
Jian-Li Liu3
Wei Yu6
Xun-Wu Meng6

1Department of Endocrinology, Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 2Metabolic Bone Disease and Genetic Research Unit, Department of Osteoporosis and Bone Disease, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, 3Department of Gynecology and Obstetrics, General Hospital of the People’s Liberation Army, Beijing, 4Department of Geriatrics, Shanghai Huashan Hospital, Shanghai, 5Department of Gynecology and Obstetrics, Beijing Hospital, Ministry of Public Health, Beijing, 6Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China

*These authors contributed equally to this work

Introduction
Osteoporosis is characterized by decreased bone strength, and it leads to increased bone fragility and susceptibility to fractures.1 Postmenopausal osteoporosis and associated fractures are major public health problems across the world, especially in the People’s Republic of China. Osteoporosis is caused by an imbalance between bone tissue formation by osteoblasts and resorption by osteoclasts.2

Osteoporosis may be prevented or treated in its early stages using basic approaches (calcium, vitamin D, diet, exercise, and smoking cessation).1 Several antistereoid drugs have been used widely for its more severe stages, and...
they have demonstrated efficacy in increasing bone mineral density (BMD) and decreasing fracture incidences. Other drugs such as bisphosphonates,\textsuperscript{1} raloxifene,\textsuperscript{4} estrogen/progestin therapy,\textsuperscript{3} and denosumab\textsuperscript{b} have also been found to be effective against osteoporosis.

Menatetrenone (vitamin K2) is known to be a cofactor of $\gamma$-carboxylase, which converts glutamic acid residues in the osteocalcin (OC) molecule to $\gamma$-carboxyglutamic acid, and it is therefore essential for $\gamma$-carboxylation of OC.$^7$–$^9$ Low vitamin K consumption is associated with a higher risk of hip fracture among older women and men.$^{10}$–$^{13}$ A meta-analysis\textsuperscript{14} has revealed that menatetrenone therapy decreases new vertebral fractures and possibly reduces long bone fractures. Menatetrenone has been approved in Japan in 1995 for treatment of postmenopausal osteoporosis; since then, it has been used widely in that country.$^{15}$

Hence, available published data are mostly obtained from a Japanese population, which may have a different pattern of risk factors (diet, exercise, and genetics) for the disease than a Chinese population. The efficacy and tolerance of menatetrenone in Chinese postmenopausal osteoporotic women has not been previously investigated. This 1-year study was therefore designed to evaluate the efficacy and safety of menatetrenone for the treatment of osteoporosis in Chinese postmenopausal women in comparison with alfacalcidol treatment. Since the study involved osteoporotic women, a placebo control was not used, and alfacalcidol was chosen as a positive drug control to demonstrate the noninferiority of these two drugs.

**Patients and methods**

**Patients**

The study was approved by the State Food and Drug Administration of China (2004L03447). This study protocol was evaluated by the ethics committee of each participating institution. All patients provided written informed consent before enrolment. Women patients included in the study had to: 1) be ambulatory; 2) aged between 45 and 75 years; 3) be postmenopausal for at least 5 years; 4) have a body mass index between 18 and 30 kg/m$^2$; 5) have a lumbar spine T-score (L2–L4) and/or femoral neck BMD lower than −2.0; and 6) be willing to provide written informed consent. Patients with the following criteria were excluded from the study: 1) disorders known to affect bone metabolism; 2) chronic diseases such as hyperthyroidism, hyperparathyroidism, osteomalacia, or diabetes; 3) treatment with bisphosphonates within the past year; 4) treatment with selective estrogen receptor modulators within the past 6 months; 5) treatment with activated vitamin D, calcitonin, estrogens, or androgens within the past 3 months; 6) treatment with warfarin; 7) chronic renal or liver disorders; and 8) history of malignant tumor. Patients were also excluded if one of these following laboratory tests was abnormal: 1) alkaline phosphatase (ALP) elevated $>10\%$ of upper normal limit; 2) alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevated $>50\%$ of upper normal limit; 3) serum creatinine levels $>133$ µmmol/L (1.5 mg/dL); and 4) fasting blood glucose $>126$ mg/dL (7.0 mmol/L).

**Study design**

This was a multicenter, randomized, double-blinded, double-dummy, noninferiority, positive drug-controlled clinical trial conducted in the following five investigational sites of the People’s Republic of China: Department of Endocrinology, Peking Union Medical College Hospital, Beijing; Department of Obstetrics and Gynecology, General Hospital of the People’s Liberation Army, Beijing; Metabolic Bone Disease and Genetic Research Unit, Department of Osteoporosis and Bone Disease, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai; Department of Geriatrics, Shanghai Huadong Hospital, Shanghai; and Department of Gynecology and Obstetrics, Beijing Hospital, Ministry of Public Health, Beijing.

No changes were made to the protocol during the study. Patients were randomized (using random number tables and sequentially numbered envelopes) in a 1:1 ratio to receive either menatetrenone (Eisai Co, Ltd, Tokyo, Japan) 15 mg, three times per day (45 mg/day) (Group M) or alfacalcidol (Haier Pharmaceutical Co, Ltd, Qingdao, People’s Republic of China) 0.25 µg, twice per day (0.5 µg/day) (Group A) for 1 year. Additionally, patients in both groups received once daily Calcichew$^\text{®}$ (Nycomed Pharma, Zurich, Switzerland), containing 500 mg of elemental calcium.

After screening and randomization (baseline), patients were followed up every 3 months. At each visit, occurrence and nature of the adverse effects were recorded for each patient. Blood levels of calcium and phosphorus, routine blood examination, urine routine examination, kidney function (creatinine), blood urea nitrogen, liver function tests (AST and ALT), and ALP were tested at months 0, 6, and 12. Biochemical markers of bone metabolism such as serum total OC and undercarboxylated OC (ucOC) were also measured at months 0, 6, and 12.

Serum OC and ucOC were measured by a central laboratory (National Center for Clinical Laboratory, Beijing, People’s Republic of China) using an electrochemiluminescence assay (Roche Diagnostics, Basel, Switzerland;
intra-assay coefficient of variation [CV] of 2.2% and inter-assay CV of 5.9%) and an enzyme-linked immunosorbent assay (Takara Bio, Otsu, Japan; intra-assay CV of 4.2% and inter-assay CV of 4.4%).

BMDs were measured at the lumbar spine and hip by dual energy X-ray absorptiometry (phantom CV <1.5%). Results at baseline and at months 6 and 12 were recorded. In order to obtain an optimal concordance between measurements from different centers, each imaging instrument was cross-calibrated using an external phantom (Synarc Inc, Newark, CA, USA). Calibration differences between individual scanners within a scanner family (ie, Lunar or Hologic) were adjusted using the results of the cross-calibration phantom. Systematic differences between the Lunar and Hologic scanners were adjusted using in vivo cross-calibration formulae from reported research studies.\(^\text{16,17}\) Lumbar and thoracic spine X-ray radiographs were taken at baseline and month 12. Morphometric vertebral fractures were defined as a decrease of >20% in vertebral height (minimum, 4 mm) by quantitative morphometry in radiographs.\(^\text{18}\)

The primary endpoints were to evaluate the effects of treatment on BMD at the lumbar spine and hip. The secondary endpoints were to assess the effects of treatment on serum biochemical markers including serum OC, ucOC, and ucOC/OC ratio. The secondary endpoints also included the onset of new fractures and falls during observation.

### Statistical analysis

The data analysis plan was finalized before database lock and unblinding. Analyses were carried out based on the intention-to-treat principle. Efficacy analysis was completed for the per-protocol set, including all patients who had undergone randomization, except for 23 patients who dropped out during the study (Group M: n=108; Group A: n=105). Safety analysis was performed for the safety set, and they included patients who had received at least one treatment dose, with the last available data in all subsequent measuring points (Group M: n=118; Group A: n=118). All follow-up measurements were compared to the baseline values, and the change rates were calculated for each patient. Due to skewed distribution, the percentage change from the baseline of BMD was presented as the median. P-values of BMD compared with the baseline within each group were based on change from baseline. Differences within and between groups were tested by the Wilcoxon signed-rank test and Wilcoxon rank-sum test, respectively. Safety data were summarized for patients with adverse events for each group. Statistical analyses were performed using SAS v8 (SAS Institute Inc, Cary, NY, USA). A P-value <0.05 (two sides) was considered statistically significant.

### Results

#### Patients

A total of 236 eligible women with postmenopausal osteoporosis were enrolled in the study, and they were randomly assigned to receive menatetrenone or alfacalcidol (n=118 each). Among them, 213 patients (90.3%) completed the 1-year follow-up period, and 23 patients withdrew prematurely. In Group M, ten patients withdrew (adverse event =4, protocol violation =1, and nonmedical reason =5); and in Group A, 13 patients withdrew (adverse event =8, nonmedical reason =5).

#### Baseline characteristics

Patients’ baseline characteristics are summarized in Table 1. There were no significant differences between the two groups for any variable. Also, there were no differences in blood pressure, routine blood analyses, routine urine analyses, and liver and kidney function tests between the two groups (data not shown).

### Changes in BMD

Compared with baseline, BMD in Group M significantly increased by 1.2% and 2.7% at the lumbar spine and

### Table 1 Baseline characteristics of the patients subjected to efficacy analysis

<table>
<thead>
<tr>
<th></th>
<th>Menatetrenone</th>
<th>Alfacalcidol</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>108</td>
<td>105</td>
<td>0.649</td>
</tr>
<tr>
<td>Age, years</td>
<td>64.6±6.1</td>
<td>64.2±6.3</td>
<td></td>
</tr>
<tr>
<td>Years since menopause</td>
<td>15.1±6.5</td>
<td>15.6±6.6</td>
<td>0.591</td>
</tr>
<tr>
<td>Height, cm</td>
<td>154.2±5.4</td>
<td>155.0±5.0</td>
<td>0.267</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>55.2±7.2</td>
<td>56.2±7.3</td>
<td>0.322</td>
</tr>
<tr>
<td>Previous vertebral fracture, number (%)</td>
<td>14 (13.0)</td>
<td>12 (11.4)</td>
<td>0.732</td>
</tr>
<tr>
<td>Bone mineral density, mg/cm²</td>
<td>805.0±15.1</td>
<td>793.7±99.9</td>
<td>0.654</td>
</tr>
<tr>
<td>Lumbar spine</td>
<td>805.0±15.1</td>
<td>793.7±99.9</td>
<td></td>
</tr>
<tr>
<td>Femoral neck</td>
<td>644±101.1</td>
<td>654.1±97.8</td>
<td>0.374</td>
</tr>
<tr>
<td>Trochanter</td>
<td>561.0±94.1</td>
<td>567.8±81.5</td>
<td>0.644</td>
</tr>
<tr>
<td>Serum calcium, mmol/L</td>
<td>2.37±0.09</td>
<td>2.37±0.11</td>
<td>0.796</td>
</tr>
<tr>
<td>Serum phosphate, mmol/L</td>
<td>1.25±0.15</td>
<td>1.23±0.18</td>
<td>0.434</td>
</tr>
<tr>
<td>Serum total ALP, U/L</td>
<td>75.5±19.4</td>
<td>73.7±18.9</td>
<td>0.479</td>
</tr>
<tr>
<td>Serum OC, ng/mL</td>
<td>27.8±8.5</td>
<td>26.1±8.5</td>
<td>0.088</td>
</tr>
<tr>
<td>Serum ucOC, ng/mL</td>
<td>2.7±2.2</td>
<td>2.4±1.9</td>
<td>0.305</td>
</tr>
<tr>
<td>Serum ucOC/OC</td>
<td>0.09±0.06</td>
<td>0.09±0.07</td>
<td>0.509</td>
</tr>
</tbody>
</table>

**Abbreviations:** ALP, alkaline phosphatase; OC, osteocalcin; ucOC, undercarboxylated osteocalcin.
trochanter, respectively, after 12 months of treatment ($P<0.001$). In Group A, BMD significantly increased by 2.2% and 1.8% at the lumbar spine and trochanter, respectively ($P<0.001$). There were no significant changes in the femoral neck BMD in both groups. There was no significant difference between the two groups after 6 and 12 months of treatment ($P>0.05$) (Figure 1).

**Changes in OC and ucOC**

Figure 2 shows the effects of treatment on serum OC and ucOC levels and on the ucOC/OC ratio. In Group M, after 12 months of treatment, OC and ucOC decreased by 38.7% and 82.3%, compared with baseline ($P<0.001$). In Group A, OC and ucOC also decreased by 25.8% and 34.8%, respectively ($P<0.001$). The decreases in serum OC and ucOC levels were more obvious in Group M than in Group A ($P<0.001$). The ucOC/OC ratios also decreased after treatment, especially in Group M (Group M: $P<0.001$; Group A: $P<0.05$) (Figure 2).

**Changes in serum calcium, phosphorus, and ALP**

In Group M, serum calcium was $2.37\pm0.09$ mmol/L, $2.42\pm0.12$ mmol/L, and $2.44\pm0.12$ mmol/L at baseline, and after 6 and 12 months of treatment, respectively. Serum phosphorus was $1.25\pm0.15$ mmol/L, $1.26\pm0.17$ mmol/L, and $1.27\pm0.18$ mmol/L at baseline and after 6 and 12 months of treatment, respectively. Serum ALP was $75.5\pm19.4$ U/L,
72.6±24.0 U/L, and 72.2±19.1 U/L at baseline, and after 6 and 12 months of treatment, respectively. There was no significant difference between the changes of serum calcium, phosphorus, and ALP before and after treatment (all P>0.05). In Group A, serum calcium was 2.37±0.11 mmol/L, 2.43±0.14 mmol/L, and 2.43±0.13 mmol/L at baseline and after 6 and 12 months of treatment, respectively. Serum phosphorus was 1.23±0.18 mmol/L, 1.28±0.17 mmol/L, and 1.23±0.18 mmol/L at baseline, and after 6 and 12 months of treatment, respectively. Serum ALP was 73.7±18.9 U/L, 73.0±18.6 U/L, and 70.3±16.5 U/L at baseline, and after 6 and 12 months of treatment, respectively. There was no significant difference between the changes of serum calcium, phosphorus, and ALP before and after treatment (all P>0.05). There was no significant difference between the two groups after 6 and 12 months of treatment (all P>0.05).

New bone fractures and falls
Two patients (1.85%, 2/108) in Group M suffered new bone fractures during the 1-year observation period, which included one tibia fracture and one femoral neck fracture. In Group A, four patients (3.81%, 4/105) suffered new fractures, which included three lumbar spine compressive fractures and one forearm fracture. Thirteen patients (12.04%, 13/108) in Group M experienced new falls during the 1-year observation period, while ten patients (9.52%, 10/105) in Group A experienced new falls. There were no significant differences in new bone fractures and falls between the two groups (P>0.05).

Safety analysis
The safety profile was similar between menatetrenone and alfacalcidol. The incidence of related adverse events was 7.7% in Group M and 5.1% in Group A. Related adverse events reported during the study are shown in Table 2. Four patients in Group M and eight patients in Group A dropped out of the study due to adverse events. The majority of these adverse events were gastrointestinal symptoms and were of mild to moderate intensity. Serum ALT or/and AST were mildly elevated (73 U/L, 155 U/L) in two patients in Group M at month 12. However, their liver function returned to within the normal range after 2 and 8 months, respectively. Transient hypercalcemia and leukocytopenia were observed in Group M. Unrelated adverse events included bone pain (1.7% in Group M and 0.9% in Group A) and joint pain (6.8% in Group M and 3.4% in Group A), which were mild and showed no difference between the two groups. No other clinically significant unexpected adverse events were reported in either group during the study.

Discussion
The present study investigated the efficacy and safety of menatetrenone in Chinese postmenopausal osteoporotic women. A significant increase in BMD by 1.2% and 2.7% at the lumbar spine and trochanter, respectively, from baseline and a significant decrease in OC and ucOC by 38.7% and 82.3%, respectively, from baseline were observed with menatetrenone treatment. Moreover, the safety profile of menatetrenone was similar to alfacalcidol. Being the first clinical trial to investigate the effects of menatetrenone on a Chinese population, the study results could provide a valid clinical basis on treating osteoporosis.

Since the study involved postmenopausal osteoporotic women (BMD T-score less than −2.0), placebo control was not used due to ethical reasons. Alfacalcidol is a recognized drug in treating osteoporosis in the People’s Republic of China. Studies in Japan showed no differences in BMD changes between menatetrenone and alfacalcidol in postmenopausal women. Therefore, alfacalcidol was chosen as a positive drug control to demonstrate the noninferiority of these two drugs. Results showed that menatetrenone 45 mg/day could significantly improve lumbar spine and trochanter BMD after 12 months of treatment. The dose of menatetrenone (45 mg/day) used in this study is the standard dose to treat osteoporosis. As per the primary osteoporosis diagnosis and treatment guidelines of the Chinese Society of Osteoporosis and Bone Mineral Research, the dose of alfacalcidol in treating osteoporosis is 0.5–1.0 µg/day. In order to avoid the side effect of high dose alfacalcidol such as hypercalcemia and hypercalciuria, a low dose of 0.5 µg/day alfacalcidol was used in this study. No differences were observed between menatetrenone and alfacalcidol (1.2% versus 2.2% in the lumbar spine, and 2.7% versus 1.8% in the trochanter, respectively) with respect to changes in BMD. However, menatetrenone had more effect on OC and ucOC than alfacalcidol.

Table 2 Related adverse events during the study

<table>
<thead>
<tr>
<th>Related side effects</th>
<th>Group M (n=118)</th>
<th>Group A (n=118)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constipation</td>
<td>2 (1.71%)</td>
<td>0</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>1 (0.85%)</td>
<td>5 (4.24%)</td>
</tr>
<tr>
<td>Abdominal distension</td>
<td>2 (1.71%)</td>
<td>2 (1.69%)</td>
</tr>
<tr>
<td>Esophagus burning</td>
<td>1 (0.85%)</td>
<td>0</td>
</tr>
<tr>
<td>Dysfunction of stomach intestine</td>
<td>2 (1.71%)</td>
<td>1 (0.85%)</td>
</tr>
<tr>
<td>Gastritis</td>
<td>1 (0.85%)</td>
<td>0</td>
</tr>
<tr>
<td>Belching</td>
<td>1 (0.85%)</td>
<td>0</td>
</tr>
<tr>
<td>AST/ALT elevated</td>
<td>2 (1.71%)</td>
<td>0</td>
</tr>
<tr>
<td>Hypercalcemia</td>
<td>1 (0.85%)</td>
<td>0</td>
</tr>
<tr>
<td>Leukocytopenia</td>
<td>1 (0.85%)</td>
<td>0</td>
</tr>
</tbody>
</table>

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Some randomized controlled trials showed that menatetrenone had only a modest impact or no impact on BMD. In the study by Orimo et al, there were no differences observed in BMD between menatetrenone 45 mg/day and alfacalcidol 1 µg/day in 24 and 48 weeks. Although menatetrenone has only a modest effect on bone loss, it may have the potential to prevent osteoporotic fractures. Vitamin K deficiency has been reported to contribute to the occurrence of fractures in elderly women, especially hip fractures, and it is also a strong predictor of vertebral fractures in patients on hemodialysis. A randomized controlled trial suggested that vitamin K2 sustained lumbar BMD and reduced the incidence of vertebral fractures, with a reported reduction of 53% in patients with postmenopausal osteoporosis; this rate was similar to the rate reported with treatment with bisphosphonates. Knapen et al indicated that menatetrenone improved the bone strength of the femoral neck by improving femoral neck width and maintaining the indices of compression, bending, and impact strength. These could lead to a decreased incidence of clinical fractures. In the present study, 1.9% of patients experienced a new fracture in Group M during 1 year of treatment, while this proportion was 3.8% in Group A; however, there was no significant difference between the two groups. There was also no difference in new falls between the two groups.

Menatetrenone is thought to be involved in bone formation as an essential cofactor for γ-carboxylation of OC. Rapid conversion of ucOC to carboxylated OC following menatetrenone treatment was confirmed in elderly osteoporotic women with vertebral fractures. The present study’s results show that OC and ucOC decreased by 38.7% and 82.3%, respectively, compared with baseline. The ucOC/OC ratio also decreased. Another study showed that menatetrenone reduced serum ucOC levels, and a study even showed a decrease in serum ucOC levels after 1 month of therapy. However, the results on serum total OC levels are inconsistent. Some studies showed an increase in serum total OC levels, while another showed a decrease in serum total OC levels by vitamin K2 supplementation. Two explanations can be proposed for this discrepancy: 1) since more OC becomes carboxylated and functional with the improvement of vitamin K2 status, a lesser amount is synthesized and released into circulation; and 2) more functional OC is bound into bones rather than circulating in the blood stream, thus lowering serum total OC levels. Studies have shown that ucOC, but not total OC, is a marker predicting hip fracture in elderly women.

Menatetrenone tolerability was also evaluated in this study. The safety profile of menatetrenone was similar to alfacalcidol. Adverse events included gastrointestinal symptoms, mild and transient hypercalcemia, leukocytopenia, and abnormalities in liver function. No severe side effects were ever reported before for menatetrenone. Even in this study, menatetrenone was well tolerated by Chinese postmenopausal women. Moreover, the treatment with menatetrenone is a pharmacoeconomically viable option.

There are some limitations to this study. The sample size was not large enough, and trial duration was not long enough to evaluate the risk of fracture as the primary endpoint. However, results did show important short-term effects in BMD, OC, and ucOC levels, suggesting that these short-term changes should have an impact on the long-term risk of fractures. Also, a food frequency questionnaire was not performed to calculate vitamin K intake. Biochemical markers reflecting bone turnover were not measured. However, changes in BMD directly reflected the balance between bone resorption and bone deposition, and the study results showed that menatetrenone supplementation had a positive impact on BMD.

**Conclusion**

After 1 year of treatment with menatetrenone, BMD at the lumbar spine and hip were significantly increased in Chinese postmenopausal osteoporotic women, and that effect was comparable to alfacalcidol. These positive changes in BMD were reflected by changes in markers of bone metabolism, and menatetrenone had more effects on these markers. Menatetrenone was well tolerated and safe in the study population. Thus, menatetrenone is an effective and safe choice for the treatment of postmenopausal osteoporosis in Chinese women.

**Acknowledgments**

This study was financially supported by Eisai China Inc. The authors thank Haier Pharmaceutical Co, Ltd, which supported this study by supplying alfacalcidol. The authors thank DMS for completing the statistical analysis of the results.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


